Author/Authors :
Lavasani, Hoda tehran university of medical sciences tums - Faculty of Pharmacy - Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, تهران, ايران , Sheikholeslami, Behjat tehran university of medical sciences tums - Faculty of Pharmacy - Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, تهران, ايران , Ardakani, Yalda H tehran university of medical sciences tums - Faculty of Pharmacy - Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, تهران, ايران , Abdollahi, Mohammad tehran university of medical sciences tums - Faculty of Pharmacy, Pharmaceutical Sciences Research Centre - Department of Pharmacology and Toxicology, تهران, ايران , Hakemi, Lida tehran university of medical sciences tums - Faculty of Pharmacy - Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, تهران, ايران , Rouini, Mohammad-Reza tehran university of medical sciences tums - Faculty of Pharmacy, Pharmaceutical Sciences Research Centre - Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, تهران, ايران
Abstract :
Background: Besides the pathological states, diabetes mellitus may also alter the hepatic biotransformation of pharmaceutical agents. It is advantageous to understand the effect of diabetes on the pharmacokinetic of drugs. The objective of this study was to define the pharmacokinetic changes of tramadol and its main metabolites after in vivo intraperitoneal administration and ex vivo perfused liver study in diabetic rat model. Tramadol (10 mg/kg) was administered to rats (diabetic and control groups of six) intraperitoneally and blood samples were collected at different time points up to 300 min. In a parallel study, isolated liver perfusion was done (in diabetic and control rats) by Krebs-Henseleit buffer (containing 500 ng/ml tramadol). Perfusate samples were collected at 10 min intervals up to 180 min. Concentration of tramadol and its metabolites were determined by HPLC. Results: Tramadol reached higher concentrations after i.p. injection in diabetics (Cmax of 1607.5 ± 335.9 ng/ml) compared with control group (Cmax of 561.6 ± 111.4). M1 plasma concentrations were also higher in diabetic rats compared with control group. M2 showed also higher concentrations in diabetic rats. Comparing the concentration levels of M1 in diabetic and control perfused livers, showed that in contrast to intact animals, the metabolic ratios of M1 and M5 (M/T) were significantly higher in diabetic perfused liver compared to those of control group. Conclusions: The pharmacokinetic of tramadol and its three metabolites are influenced by diabetes. As far as M1 is produced by Cyp2D6, its higher concentration in diabetic rats could be a result of induction in Cyp2D6 activity, while higher concentrations of tramadol can be explained by lower volume of distribution.
